By using the CRISPR-dCas13d-eIF4G platform, researchers enhanced GPX4 expression in renal epithelial cells, which reduced calcium oxalate-induced ferroptosis and kidney stone formation in both human cells and mouse models (He et al., 2024). Here, GPX4 is linked to nephrolithiasis.